People · Operator
Named in public records as an officer, director or promoter · active 2019–2024 · Pharmaceuticals, Biotechnology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Paragon Biosciences Emalex Capital, Inc. | — | Pharmaceuticals | Series D+ | $376.8M | $5.5B | 2022 |
| Evozyne, Inc. | — | Biotechnology | Series C | $144.4M | $979.0M | 2020 |
| CIRC Biosciences, Inc. | — | Biotechnology | Series B | $24.1M | $54.7M | 2020 |
| Paragon Biosciences CIRC Holdings, LLC | — | Biotech / Pharma | Series B | $15.8M | $512.4M | 2020 |
| Paragon Biosciences Qlarity Capital, Inc. | — | Pharmaceuticals | Series B | $15.0M | $510.1M | 2019 |
| Paragon Biosciences Evozyne Capital, LLC | — | Biotechnology | Series A | $9.5M | $342.5M | 2020 |
| Paragon Biosciences Evozyne Holdings, LLC | — | Biotechnology | Series A | $9.0M | $325.4M | 2020 |
Darien J. Parhad at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Darien J. Parhad on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.